 Cancer Genetics, Inc. CGIX, a leader in proprietary preclinical test systems supporting drug discovery and development at early stages, valued by the pharmaceutical industry, biotechnology companies and academic research centers, today announced, among others, the completion of several strategic transactions. As the result of the previously announced sale of the companys BioPharma business to Interpace Diagnostics Group, Inc. IDXG or its affiliate, IDXG or its affiliate paid approximately 6 million in cash to CGIX on October 24, 2019, as partial settlement of a promissory note in the original face amount of approximately 7.7 million due to CGIX. 